Evidence map›Paper›PMID 27316471›Full record

ArticleIndian heart journal

Will percutaneous valves replace the surgical valves: Another one bites the dust?

Sundeep Mishra

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. TAVR-present, future, and challenges in developing countries.Indian journal of thoracic and cardiovascular surgery · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sundeep MishraProfessor of Cardiology, AIIMS, New Delhi, India. Electronic address: sundeepmishraihj@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trans-cutaneous valve implantation (TAVI) has witnessed rapid evolution in terms of technical design, efficacy, and safety outcomes. This has led to expanding indications of TAVI from inoperable to high surgical to now even lower surgical risk patients. However, its cost and applicability only in elderly patients with degenerated valves is a cause of concern limiting the use of this technology. Further evolution may lead to its application in lower risk essentially younger patients with broader etiologic sub-groups.

Indexed as

Heart Valve ProsthesisAgedAortic ValveAortic Valve StenosisHumansProsthesis DesignTranscatheter Aortic Valve ReplacementAortic stenosisCoreValve(®)Cost effectivenessElderlyPercutaneous valveProsthetic valve degenerationProsthetic valve functionSapien XT(®)SAVRTAVITAVR

Identifiers

PMID27316471
PMCPMC4911450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.